文献速递衰弱、肌少症与跌倒老年慢病共病管理

移动输注单元为护理机构COVID-19患者提供单克隆抗体治疗

A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities.
PubMed 文献 · J Am Geriatr Soc · 2021-03-05

结论认为移动输注单元可快速为无法获取治疗的高风险患者提供单克隆抗体,耐受性良好且可能有益。

要点

  • 移动输注单元可为熟练护理机构高风险COVID-19居民快速提供单克隆抗体治疗
  • 45例接受输注的患者平均年龄77.8岁,输注在诊断后平均4.3天进行

核心结论

  • 移动输注单元嵌入协作流程可快速为熟练护理机构中无法获取新疗法的高风险COVID-19患者输注单克隆抗体。
  • 该疗法耐受性良好且似乎有益,但需进一步研究可扩展性和有效性。

研究设计与样本

  • 回顾性队列研究,由Mayo Clinic与明尼苏达州东南部熟练护理机构合作开展。
  • 在FDA紧急使用授权下给予抗刺突单克隆抗体,纳入75名COVID-19并发症高风险的熟练护理机构居民。

主要发现

  • 输注发生在COVID-19诊断后平均4.3天。
  • 报告1例不良事件。

关键数值与推荐

  • 暴露为bamlanivimab和casirivimab-imdevimab的紧急使用治疗。
  • 结局指标为住院和医疗就诊事件。

临床怎么用

  • 对于熟练护理机构中高风险COVID-19居民,可考虑通过移动输注单元提供单克隆抗体治疗以克服衰弱和后勤障碍。

局限性

  • 原文为回顾性描述性研究,样本量有限,需进一步研究可扩展性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Residents of nursing homes and long-term care facilities are at increased risk for severe coronavirus disease-19 (COVID-19) but may not be able to access monoclonal antibody therapies offered at outpatient infusion centers due to frailty and logistical issues. We describe a mobile monoclonal antibody infusion program for patients with COVID-19 in skilled nursing facilities and provide descriptive data on its outcomes. DESIGN: Retrospective cohort study. SETTING: Collaboration between Mayo Clinic and skilled nursing facilities in Southeast Minnesota was developed to administer anti-spike monoclonal antibodies under the FDA Emergency Use Authorization. PARTICIPANTS: Seventy five residents of skilled nursing facilities at high risk of COVID-19 complications. EXPOSURE: Emergency use treatment with bamlanivimab and casirivimab-imdevimab. MEASUREMENTS: Hospitalization and medically attended visits. RESULTS: The mobile infusion unit, staffed by Mayo Clinic Infusion Therapy registered nurses and supported by the skilled nursing facility staff, infused anti-spike monoclonal antibodies to 45 of 75 patients (average age, 77.8 years) in December 2020. The infusions occurred at an average of 4.3 days after COVID-19 diagnosis. Fourteen days after infusion, there were no deaths, two emergency department visits, and three hospitalizations, for a combined event rate of 11.1%. There was one reported adverse event. CONCLUSION: The implementation of a mobile infusion unit embedded in a collaborative process resulted in rapid infusion of monoclonal antibodies to high-risk COVID-19 patients in skilled nursing facilities, who would otherwise be unable to access the novel therapies. The therapies were well tolerated and appear beneficial. Further study is warranted to explore the scalability and efficacy of this program.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Tulledge-Scheitel S, Bell SJ, Larsen JJ, et al. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities. J Am Geriatr Soc. 2021. PMID: 33619724. doi:10.1111/jgs.17090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。